RMC-6291

RMC-6291 is an orally active and covalent inhibitor of KRAS^G12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRAS^G12C(ON) and cyclophilin A (CypA). RMC-6291 elicits deep and durable suppression on RAS pathway activity in KRAS^G12C tumor models.


Cat. No.: EX-A7663	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
5mg	750	In-stock
10mg	1100	In-stock
25mg	get quote	In-stock
50mg	get quote	In-stock
100mg	get quote	In-stock
500mg	get quote	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	2641998-63-0
Purity	>98%
Formula	C55H78FN9O8
Mol Weight	1012.2617
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Schulze, Christopher J et al. “Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.” Science (New York, N.Y.) vol. 381,6659 (2023): 794-799. [2]. Nichols R J, et al. RMC-6291, a next-generation tri-complex KRASG12C (ON) inhibitor, outperforms KRASG12C (OFF) inhibitors in preclinical models of KRASG12C cancers[J]. Cancer Research, 2022, 82(12_Supplement): 3595-3595.
Data Sheet	Data sheet of RMC-6291
CoA	CoA of RMC-6291
SDS	SDS of RMC-6291


		Search